We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Precise Cancer Detection Method as Quick and Easy as Blood Test

By LabMedica International staff writers
Posted on 04 Jun 2024

Researchers have unveiled a groundbreaking method to detect cancer, potentially simplifying the process to just taking a blood test. More...

This technique, which boasts a 98.7% accuracy rate, combines optical imaging technology with fluorescent imaging. The method’s capability to identify cancer at its initial stages could significantly enhance the effectiveness of treatments.

The highly accurate method developed by a research team at the University of Houston (Houston, TX, USA) enables the examination of extracellular vesicles or EVs—nanometer-sized membrane sacs present in the bloodstream that can transport various cargoes, including proteins, nucleic acids, and metabolites. In 2020, the research team introduced PANAROMA, an optical imaging technology featuring a glass slide covered with gold nanodiscs. This setup permits the observation of light transmission changes and the determination of nanoparticles as small as 25 nanometers in diameter. The technology's name, PANORAMA, stands for Plasmonic Nano-aperture Label-free Imaging, highlighting its critical features. For this particular study, the focus was on counting small EVs to detect cancer.

By setting a cutoff of 70 normalized small EV counts, the team noted that all cancer samples from 205 patients surpassed this threshold except for one. Conversely, among the healthy samples from 106 individuals, only three did not meet this threshold. This resulted in a cancer detection sensitivity of 99.5% and a specificity of 97.3%. Further testing of the 70 normalized small EV count threshold was conducted on two independent sample sets from patients with stage I-IV or recurrent leiomyosarcoma/gastrointestinal stromal tumors and early-and-late-stage cholangiocarcinoma. These samples were anonymously labeled and mixed with healthy samples, where the method achieved 100% accuracy. The team's findings were published in Nature Communications Medicine on May 25, 2024

“We observed differences in small EV numbers and cargo in samples taken from healthy people versus people with cancer and are able to differentiate these two populations based on our analysis of the small EVs,” said Wei-Chuan Shih, Cullen College of Engineering professor of electrical and computer engineering. “With further optimization, our approach may be a useful tool for cancer detection screening in particular and provide insights into the biology of cancer and small EVs.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Urine Analyzer
respons® UDS100
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.